Day: March 8, 2022

SALISBURY, Md., March 08, 2022 (GLOBE NEWSWIRE) — Partners Bancorp (NASDAQ: PTRS) (the “Company”), the parent company of The Bank of Delmarva (“Delmarva”), Seaford, Delaware, and Virginia Partners Bank (“Virginia Partners”), Fredericksburg, Virginia, reported net income attributable to the Company of $1.5 million, or $0.08 per share, for the three months ended December 31, 2021, a $351 thousand or 31.6% increase when compared to net income attributable to the Company of $1.1 million, or $0.06 per share, for the same period in 2020. For the twelve months ended December 31, 2021, the Company reported net income attributable to the Company of $7.4 million, or $0.42 per share, a $1.7 million or 30.7% increase when compared to net income attributable to the Company of $5.7 million, or $0.32 per share, for the same period in 2020. As...

MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need it with the best neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2021. Fourth Quarter 2021 HighlightsExceeded guidance – Fourth quarter 2021 revenue of $15.0 million, exceeded previously issued guidance of $13.0 to $14.0 million Increased revenue – Fourth quarter 2021 revenue increased 9% sequentially as compared to third quarter 2021 Achieved record-breaking quarterly treatment session revenue – Fourth quarter 2021 U.S. treatment session revenue of $11.2 million, compared to $11.0 million in fourth quarter 2020Full...

– CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year –- – Published CGuard Clinical trial results in Journals of the American College of Cardiology – – Established Reimbursement Approval for CGuard from the French National Authority – – CGuard Included as Carotid Stent Treatment Option in National Institute of Neurological Disorders and Stroke (NINDS) Sponsored CREST-2 Trial Following FDA Approval of IDE Supplement Application – —Management to Host Investor Conference Call Today, March 8, at 8:30am ET— TEL AVIV, Israel, March 08, 2022 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease, today announced financial and...

Earned $35 million milestone payment as NIS793 entered Phase 3 clinical study in metastatic pancreatic cancer Received $1.2 million from three milestone payments, two of which were from a single Janssen asset and one was from Compugen Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in early 2022 Acquired an economic interest in Roche’s novel bispecific antibody from Affitech SA.  This asset has since received commercialization approval from the U.S. Food and Drug Administration (FDA) for the treatment of neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME).  We paid Affitech SA $5 million in milestones upon these approvals Three drug candidates being advanced by partners received special designations...